Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 750

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Acute myeloid leukaemia (in remission)

Not recruiting

Study on the Effectiveness of Decitabine and Venetoclax for Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine

Anaemia+1

Not recruiting

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Short-bowel syndrome

Not recruiting

Long-term safety study of apraglutide (weekly injections) in patients with Short Bowel Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apraglutide

Pseudomonas infection

Not recruiting

Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Waldenstrom's macroglobulinaemia

Not recruiting

Study of CLR 131 for Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine Sodium

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Ocrelizumab

Myasthenia gravis

Not recruiting

Study on the Effectiveness and Safety of Batoclimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Efficacy of Linsitinib for Patients with Active, Moderate to Severe Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Linsitinib

Non-small cell lung cancer

Not recruiting

Study of AMG 193 and IDE397 for Adults with Advanced MTAP-null Solid Tumors and Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Amg 193

Multiple sclerosis relapse

Not recruiting

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Ofatumumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.